Seongyeong Kim
Overview
Explore the profile of Seongyeong Kim including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
268
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Han T, Lee J, Seo B, Jeon W, Yang H, Kim S, et al.
Ecotoxicol Environ Saf
. 2022 Nov;
248:114334.
PMID: 36442398
Owing to their unique properties and biological activities, ionic liquids (ILs) have attracted research interest in pharmaceutics and medicine. Hypoxia-inducible factor (HIF)- 1α is an attractive cancer drug target involved...
2.
Kang W, Maher L, Michaud M, Bae S, Kim S, Lee H, et al.
Biol Proced Online
. 2021 Apr;
23(1):9.
PMID: 33827419
No abstract available.
3.
Kim S, Shin D, Min A, Kim M, Na D, Lee H, et al.
J Transl Med
. 2021 Jan;
19(1):7.
PMID: 33407601
Background: Metastatic breast cancer (mBC) is a complex and life-threatening disease and although it is difficult to cure, patients can benefit from sequential anticancer treatment, including endocrine therapy, targeted therapy...
4.
Kang W, Maher L, Michaud M, Bae S, Kim S, Lee H, et al.
Biol Proced Online
. 2021 Jan;
23(1):1.
PMID: 33390162
Background: Gastric cancer metastasis is a highly fatal disease with a five-year survival rate of less than 5%. One major obstacle in studying gastric cancer metastasis is the lack of...
5.
Homologous repair deficiency score for identifying breast cancers with defective DNA damage response
Min A, Kim K, Jeong K, Choi S, Kim S, Suh K, et al.
Sci Rep
. 2020 Jul;
10(1):12506.
PMID: 32719318
Breast cancer (BC) in patients with germline mutations of BRCA1/BRCA2 are associated with benefit from drugs targeting DNA damage response (DDR), but they account for only 5-7% of overall breast...
6.
Ha D, Min A, Kim S, Jang H, Kim S, Kim H, et al.
Sci Rep
. 2020 Jun;
10(1):9930.
PMID: 32555285
Due to its regulation of CDK1/2 phosphorylation, WEE1 plays essentially roles in the regulations of G2/M checkpoint and DNA damage response (DDR). WEE1 inhibition can increase genomic instability by inducing...
7.
Shin J, Kim S, Ha S, Choi B, Kim S, Im S, et al.
Biomolecules
. 2019 Oct;
9(10).
PMID: 31635022
G309 or S310 mutations on the HER2 extracellular domain II induce receptor activation. Clinically, S310F is most frequent among HER2 extracellular domain mutations and patients with the S310F mutation without...
8.
Min A, Jang H, Kim S, Lee K, Kim D, Suh K, et al.
Mol Cancer Ther
. 2018 Sep;
17(12):2507-2518.
PMID: 30232143
The androgen receptor (AR) is expressed in 60%-70% of breast cancers regardless of estrogen receptor status, and has been proposed as a therapeutic target in breast cancers that retain AR....
9.
Lee M, Lee K, Min A, Kim J, Kim S, Jang H, et al.
Cancer Res Treat
. 2018 Jun;
51(2):451-463.
PMID: 29879757
Purpose: Pim kinases are highly conserved serine/threonine kinases, and different expression patterns of each isoform (Pim-1, Pim-2, and Pim-3) have been observed in various types of human cancers, including gastric...
10.
Min A, Kim J, Kim Y, Lim J, Kim S, Kim J, et al.
Cancer Lett
. 2018 May;
430:123-132.
PMID: 29729292
Palbociclib is a specific inhibitor of CDK4/6 and has been shown to provide a survival benefit in hormone receptor-positive advanced breast cancer. TCGA database reported that about half of gastric...